Navigation Links
Bone Biologics Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Date:9/16/2013

NEW YORK, Sept. 16, 2013 /PRNewswire/ -- Bone Biologics today announced its September 12th RetailInvestorConferences.com presentation is now available for on-demand viewing.  

Bone Biologics's presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the "virtual trade booth" for the next three weeks.

LINK:    www.retailinvestorconferences.com > click on the red "register/ watch event now" button

About Bone Biologics:

Bone Biologics was founded by University of California professors in collaboration with an Osaka University professor and a USC Surgeon in 2004.  Bone Biologics is a privately-held company with proprietary, patented technology that has been clinically proven in non-human primate models to facilitate bone growth. The company is currently focused on bone regeneration in spinal fusion using its recombinant human protein, known as UCB-1 (or Nell-1). UCB-1 is an osteoinductive orthobiologic: a recombinant protein that provides control over bone regeneration. This patent protected technology has been exclusively licensed to Bone Biologics from UCLA.

About RetailInvestorConferences.com:

Since 2010, RetailInvestorConferences.com has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.


'/>"/>
SOURCE Bone Biologics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Advanced Biologics Opens New and Expanded Headquarters in Carlsbad, California
2. PUR Biologics’ Novel Orthopedic Developments Supported by Two New US Patents
3. Synthetic Biologics to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City
4. KBI Biopharma Selects Freeslate’s Biologics Formulation System for Early and Late Stage Drug Development
5. Freeslate’s Biologics Formulation System Selected by Sanofi Pasteur to Improve Efficiency of Formulation Development
6. BiologicsMD, Inc. Announces Issuance of First U.S. Patent for PTH-CBD™
7. Synthetic Biologics Reports Second Quarter 2013 Financial Results and Operational Update
8. Synthetic Biologics to Report Second Quarter 2013 Financial Results
9. Synthetic Biologics Initiates Manufacturing Process for C. difficile Infectious Disease Program
10. Synthetic Biologics to Present at OneMedForum New York 2013
11. Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... ... May 22, 2017 , ... Cancer ... exhibiting in booth B2 at the Association for Pathology Informatics Annual Summit ... In addition to demonstrating its Cancer Diagnostic Cockpit and Consultation Portal, Inspirata will ...
(Date:5/18/2017)... , ... May 18, 2017 , ... ... on April 28, 2017 at the Prince Of Wales Private Hospital. The procedure ... at level C6-C7. The patient failed conservative treatments prior to undergoing surgery. , ...
(Date:5/18/2017)... ... May 17, 2017 , ... ... medical device compliance and commercialization, has just released version 9.0 of the Cognition ... this latest version of Cockpit,” says David Cronin, CEO of Cognition. “We’re thrilled ...
(Date:5/18/2017)... ... ... was notified earlier this year that his company Asymmetrex had been selected as ... Review , he was not surprised as others might be. Sherley says, “I felt ... Valley was particularly meaningful. Our selection by The Silicon Review may seem ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... -- Trends, opportunities and forecast in this market to ... AFIS, iris recognition, facial recognition, hand geometry, vein recognition, ... industry (government and law enforcement, commercial and retail, health ... and by region ( North America , ... , and the Rest of the World) ...
Breaking Biology News(10 mins):